Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RPS6KA2 | Q15349 | 11/20 | 0.40 |
| ▸ | SCD | O00767 | 2/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18674097 | 0.92 | ITK (0.41) | ITKALDH1A1RPS6KA2SCDSCD5 | |
| SCHEMBL22679253 | 0.92 | ITK (0.41) | ITKALDH1A1RPS6KA2SCDSCD5 | |
| SCHEMBL952163 | 0.91 | ITK (0.51) | ITKALDH1A1RPS6KA2SCDSCD5 | |
| SCHEMBL950895 | 0.90 | SMN1; SMN2 (0.49) | ITKALDH1A1RPS6KA2SCDSCD5 | |
| SCHEMBL950985 | 0.90 | ITK (0.44) | ITKALDH1A1RPS6KA2SCDSCD5 | |
| SCHEMBL949043 | 0.90 | ALDH1A1 (0.47) | ITKALDH1A1SCDSCD5SMN1; SMN2 | |
| SCHEMBL949336 | 0.89 | RPS6KA2 (0.46) | ITKALDH1A1RPS6KA2SCDSCD5 | |
| SCHEMBL948933 | 0.88 | L3MBTL1 (0.49) | ITKALDH1A1RPS6KA2SCDSCD5 | |
| SCHEMBL949621 | 0.88 | ITK (0.55) | ITKALDH1A1RPS6KA2SCDSMN1; SMN2 | |
| SCHEMBL19493241 | 0.87 | ITK (0.42) | ITKALDH1A1RPS6KA2SCDSCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | CHEK2, CHEK1, BUB1B | ITK 594/4885ALDH1A1 1710/4885RPS6KA2 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.